|
|
|
|
Science Sparks @ ACTREC
|
 23 February 2026 |
Vol. No. 15 ; Issue No.723 |
|
|
Publications
|
|
1. Kumar A, Gurav M, Sarkar J, Bapat P, Madhu K, Shetty O, Chatterjee A, Sahay A, Dasgupta A, Moiyadi A, Shetty P, Gupta T, Goda JS, Epari S (2026). Impact of IDH mutation and MGMT methylation as Independent prognostic markers in uniformly treated high grade glioma Patients: A Real-World evidence in the Indian Population. Brain Research. 1877-1878:150205.
2. Sandbhor P, Goda J, Banerjee R, Dyawanapelly S (2026).Targeted dual-drug delivery for minimal residual glioblastoma using multifunctional thermosensitive liposomal hydrogels. Journal of Drug Delivery Science and Technology.
3.Bentzen S, Gupta T, Jacinto A, Rosenblatt E, Bhasker S, Napoles M, Binia S, Chansilpa Y, Aguiar S, Nagarajan M, Ghosh Laskar S, Marchi P, Goloubeva O, Hopkins K, Zubizarreta E, Agarwal J, Abdel-Wahab M (2026). Hypofractionated versus normofractionated accelerated radiation therapy with or without cisplatin for locally advanced head and neck squamous cell carcinoma (HYPNO): A randomized, open-label, Phase 3, noninferiority trial. International Journal of Radiation Oncology,Biology,Physic
4. Bancroft E, Page E, McHugh J.......Greenhalgh L, Murthy V...etal. (on behalf of the IMPACT Study Collaborators ) , Brook M, Kate-Zarai Z, Eles R (2026). Targeted prostate cancer screening in carriers of BRCA1 or BRCA2 pathogenic germline variants detects clinically relevant disease: 5-year results from the IMPACT study. European Urology.
5. Guha A, Gawde J, Mahajan K, Bagal B, Parab A, Rajeshwari A, Shetty N, Kulkarni S (2026). Is looking at the tip of the iceberg sinking our ship? A longitudinal cohort study on the patterns of evolution on treatment of non-enhancing FLAIR lesions in primary CNS lymphoma. Journal of Neurooncology. 177(1):7
6. Mawalankar G, Achrekar A, Biswas S, Terse V, Joshi S, Ugale P, Bhanshe P, Chaudhary S, Kusurkar S, Shahin S, Gawde V, Shetty D, Jindal N, Mirgh S, Shetty A, Gokarn A, Punatar S, Nayak L, Jain H, Bagal B, Sengar M, Khattry N, Rajpal S, Chatterjee G, Tembhare P, Subramanian PG, Patkar N (2026). Validation and refinement of the European LeukemiaNet 2022 genetic risk stratification of AML. JCO Global Oncology.
7. Malhotra R, Moitra P, Chatterjee A, Kota PK, Dasgupta A, Epari S, Menon N, Kowtal P, Sarin R, Gupta T (2026). Clinical and genetic predictors of temozolomide-induced severe myelotoxicity in adult diffuse glioma: a case-control study. Journal of Neurooncology. 177(1):9.
|
|
|
|
|
Interesting Reads
|
|
Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z, Atduev V, Göger YE, Rausch S, Kang SH, Loriot Y, Bedke J, Galsky MD, O'Donnell PH, von Amsberg G, Alimohamed N, Sulimka G, Gupta S, Paramonov V, Nakane K, Mihm M, Meng C, Huang CD, Ramamurthy C, Homet Moreno B, Ullén A; KEYNOTE-905/EV-303 Investigators. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. New England Journal of Medicine.
|
|
|
Video of the Week
|
|
| Role of IDH as an agnostic driver alteration in cholangiocarcinoma |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 1996, FDA approved anastrozole (Arimidex) as a treatment for breast cancer. This drug blocks the production of estrogen.
|
|
|
|
Cancer News
|
| |
|
Quitting smoking for 10 years lowers risk of oral cancer by one-third: Study.
|
|
Indian Express, 20/02/2026
|
|
Presenting the paper, Dr. Rajesh Dikshit, Director of the Centre for Cancer Epidemiology, TMC, said, “This is crucial evidence for India. Buccal mucosa cancer is one of the most preventable cancers. Our findings show that cessation programmes must expand to target chewing tobacco, not just smoking...
|
| |
|
|
|
|
| |
|
|
|
Scientists discover the enzyme that lets cancer rapidly rewire its DNA.
|
|
Sciencedaily, 16/02/2026
|
|
Researchers have uncovered the enzyme behind chromothripsis, a chaotic chromosome-shattering event seen in about one in four cancers. The enzyme, N4BP2, breaks apart DNA trapped in tiny cellular structures, unleashing a burst of genetic changes that can help tumors rapidly adapt...
|
|
|
|
|
|
|
|
|
2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
